Eastbourne Comments on Election of Directors at Amylin Annual Meeting of Shareholders

Eastbourne Comments on Election of Directors at Amylin Annual Meeting of Shareholders

SAN RAFAEL, Calif.--(BUSINESS WIRE)--Eastbourne Capital Management, L.L.C. announced that, based on voting estimates from its proxy solicitor, MacKenzie Partners, Inc., at today's Annual Meeting of Shareholders at Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN), it appears that both Eastbourne and Icahn have succeeded in electing new directors to the Amylin Board. A preliminary report from the inspectors of election is expected in one to two weeks.

Richard J. Barry, Eastbourne Founder and Portfolio Manager, commented, "We want to thank Amylin shareholders for supporting us in effecting change to the Amylin Board and sending a strong message that the past results are not acceptable. We look forward to working constructively with the new Board of Amylin and doing our part to ensure the long-term success of the Company."

About Eastbourne Capital Management, L.L.C.

Eastbourne Capital Management is a West Coast-based registered investment advisor that employs an investment philosophy based on intensive research, a long-term outlook and a belief in working alongside portfolio companies to enhance shareholder value

Suggested Articles

Horizon Therapeutics is expanding its U.S. footprint to the Bay Area—the company unveiled a new R&D and manufacturing site in South San Francisco.

Azeria Therapeutics has raised £32 million ($41 million) to take its estrogen receptor positive breast cancer program into the clinic.

Biogen’s Al Sandrock has given a bullish assessment of Alzheimer’s disease drug aducanumab. The head of R&D at Biogen thinks the drug works, despite i